The Pistoia Alliance, a global not-for-profit alliance, announced results of a survey of 229 life science professionals. The survey indicated that the majority (72%) believe their sector is lagging behind other industries in its AI development.
The survey found adoption of AI is high, with more than two thirds (69%) of companies using AI, machine learning, deep learning, and chatbots; an increase from when the same question was asked last September, where under half (44%) of respondents were using or experimenting with AI. A further 19% of respondents signaled that they plan to use AI within the next 12 months, with just 12% of life science professionals not using AI at all. Of those currently using AI in their organizations, approximately a fifth (21%) felt that their projects were not yet providing meaningful outcomes, and 21% ‘didn’t know’ if projects were delivering meaningful outcomes. The Pistoia Alliance believes collaboration between interested parties will be essential in ensuring AI projects lead to results that positively impact R&D.
Additionally, The Pistoia Alliance has launched its Centre of Excellence for AI in Life Sciences to accelerate the successful use of AI. The Centre of Excellence aims to help facilitate these collaborations by allowing companies to share their expertise and knowledge, in addition to holding events that help organizations build prototypes and pilots that prove the value of AI.
The survey of 229 senior pharmaceutical and life science leaders was conducted via webinar in May 2018. For information and slides from the webinars, see here.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.